KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $1.58 $2.30 Friday, 26th Apr 2024 CTMX stock ended at $1.59. This is 0.625% less than the trading day before Thursday, 25th Apr 2024. During the day the stock fluctuated 3.77% from a day low at $1.59 to a day high of $1.65.
90 days $1.38 $2.86
52 weeks $1.04 $2.86

Historical CytomX Therapeutics prices

Date Open High Low Close Volume
Mar 07, 2016 $13.28 $13.86 $12.90 $13.22 66 900
Mar 04, 2016 $13.91 $14.18 $13.28 $13.66 120 300
Mar 03, 2016 $13.91 $14.24 $13.26 $13.75 116 400
Mar 02, 2016 $13.72 $14.29 $13.43 $14.27 88 700
Mar 01, 2016 $13.01 $14.24 $12.76 $14.06 89 900
Feb 29, 2016 $14.43 $14.70 $12.77 $12.90 84 700
Feb 26, 2016 $13.50 $16.00 $13.29 $14.44 88 000
Feb 25, 2016 $13.28 $13.35 $12.49 $13.35 14 800
Feb 24, 2016 $12.50 $12.93 $12.21 $12.75 28 400
Feb 23, 2016 $13.21 $13.40 $12.56 $12.69 50 700
Feb 22, 2016 $13.02 $13.83 $12.67 $13.17 28 300
Feb 19, 2016 $12.69 $12.99 $11.91 $12.91 27 900
Feb 18, 2016 $12.68 $13.03 $12.16 $12.73 35 900
Feb 17, 2016 $12.64 $13.24 $11.48 $12.72 143 400
Feb 16, 2016 $12.19 $15.01 $11.78 $12.50 86 800
Feb 12, 2016 $12.02 $12.97 $11.48 $12.05 83 400
Feb 11, 2016 $12.71 $13.00 $11.95 $11.98 62 100
Feb 10, 2016 $13.35 $13.98 $12.86 $13.03 20 500
Feb 09, 2016 $13.21 $13.58 $12.57 $13.40 68 200
Feb 08, 2016 $14.55 $15.97 $12.89 $13.45 39 200
Feb 05, 2016 $15.28 $16.42 $14.28 $14.72 46 900
Feb 04, 2016 $15.59 $16.70 $15.19 $15.45 23 300
Feb 03, 2016 $16.08 $16.93 $15.32 $15.68 81 000
Feb 02, 2016 $15.64 $16.00 $14.51 $16.00 86 900
Feb 01, 2016 $15.40 $16.45 $14.61 $15.86 61 000
Click to get the best stock tips daily for free!

About CytomX Therapeutics

CytomX Therapeutics CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatme... CTMX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT